Physician
PSJ Pediatrics, LLC
PSJ Pediatrics, LLC was paid $6.39M by Medicaid between Jan 2019 and Nov 2024, across 42 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 59% of everything it billed.
33Billing provider infoPSJ PEDIATRICS, LLC
COCOA, FL 32927
COCOA, FL 32927
33aNPI1922362854assigned 06/26/2012
33bProvider typePediatrics Physician
28Total paid$6.39M
24GClaims231,516
24DCodes billed42
24AFirst – last monthJan 2019 – Nov 2024
Compared with peers
Next to other Pediatrics Physician providers in Florida
Rank by total paid#51 of 971
Median peer was paid$238K
This provider vs. median27×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 37,768 | $863K | |
| 2020 | 35,055 | $952K | |
| 2021 | 41,428 | $1.24M | |
| 2022 | 50,743 | $1.37M | |
| 2023 | 44,027 | $1.18M | |
| 2024incomplete | 22,495 | $775K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 59% | 59,190 | 49,116 | $3.74M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 11% | 6,478 | 6,385 | $715K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.0% | 4,236 | 4,160 | $444K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.1% | 4,524 | 4,463 | $388K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 3.5% | 14,960 | 13,402 | $223K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.2% | 2,271 | 2,253 | $206K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.8% | 35,117 | 16,986 | $177K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.6% | 9,804 | 9,632 | $104K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 27,634 | 24,345 | $101K |
| 94010 | 1.4% | 12,711 | 11,335 | $92K | |
| 92567 | <1% | 15,649 | 13,726 | $63K | |
| 90670 | <1% | 3,260 | 3,199 | $48K |
30 more codes
| 99188 | <1% | 5,532 | $33K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 177 | $14K |
| 99381 | <1% | 122 | $10K | |
| 94664 | <1% | 7,208 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 295 | $5K |
| 83655 | <1% | 1,330 | $4K | |
| 90651 | <1% | 661 | $3K | |
| 87807 | <1% | 527 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 334 | $2K |
| 90715 | <1% | 301 | $2K | |
| 90716 | <1% | 1,833 | $2K | |
| 90686 | <1% | 867 | $1K | |
| 90633 | <1% | 1,702 | $1K | |
| 81002 | <1% | 1,286 | $920.79 | |
| 85018 | <1% | 1,419 | $819.84 | |
| 90723 | <1% | 2,603 | $619.28 | |
| 90707 | <1% | 1,824 | $309.88 | |
| 90647 | <1% | 696 | $265.91 | |
| 90700 | <1% | 1,904 | $212.14 | |
| 90681 | <1% | 973 | $125.00 | |
| 81025 | <1% | 79 | $111.03 | |
| 90734 | <1% | 237 | $98.76 | |
| 90713 | <1% | 499 | $36.89 | |
| 90648 | 0% | 2,910 | $0.00 | |
| 90677 | 0% | 226 | $0.00 | |
| 90620 | 0% | 28 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 14 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 26 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 43 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAIN, TARUN (PRESIDENT)